Background: Autologous hematopoietic cell transplantation (HCT) is a first-line therapy for prolonging survival in patients with light-chain (AL) amyloidosis. Cardiac involvement is the most important determinant of survival. However, patients with advanced cardiac involvement have often been excluded from HCT because of high risk for transplantation-related mortality and poor overall survival. Whether baseline left ventricular global longitudinal strain (GLS) can provide additional risk stratification and predict survival after HCT in this high-risk population remains unclear. The aim of this study was to evaluate the prognostic implication of baseline GLS and the added value of GLS beyond circulating cardiac biomarkers for risk stratification in patients with AL amyloidosis undergoing HCT.
Primary or systemic light-chain (AL) amyloidosis is a rare but potentially fatal plasma cell dyscrasia characterized by tissue deposition of amyloid fibrils derived from monoclonal ALs leading to progressive organ failure. 1, 2 Treatment has primarily targeted the pathologic plasma cells to terminate monoclonal AL production. First-line therapy with highdose chemotherapy followed by autologous hematopoietic cell transplantation (HCT) has resulted in complete hematologic remission (CR) and improved 5-year survival. [3] [4] [5] [6] [7] Cardiac involvement occurs in 50% of cases and is the most important determinant of survival. 2, 8 Troponin and N-terminal pro-brain natriuretic peptide (NT-proBNP) are sensitive and reproducible prognostic markers in AL amyloidosis. A prognostically validated Mayo staging system based on these biomarkers is commonly used for risk stratification and prediction of overall survival (OS) in newly diagnosed patients undergoing frontline therapy, including HCT. [9] [10] [11] Patients are classified as stage I, II, or III on the basis of whether both NT-proBNP and troponin levels are normal, whether one biomarker is increased, or whether both are elevated, respectively. Survival decreases with each higher stage, as increasing stage correlates with the severity of underlying cardiac involvement. Patients with advanced cardiac amyloidosis classified as Mayo stage III (elevated troponin and NT-proBNP) are often not considered for HCT, because of high risk for transplantationrelated mortality and poor OS. 12 Echocardiography provides diagnostic and prognostic information in patients with AL amyloidosis suspected of having cardiac involvement. [13] [14] [15] [16] [17] [18] Multiple echocardiographic parameters are predictive of outcomes. Recently, myocardial strain by twodimensional (2D) speckle-tracking echocardiography has emerged as a highly useful tool in the evaluation of patients with cardiac amyloidosis. [19] [20] [21] [22] Global longitudinal strain (GLS) has shown to be a strong and independent predictor of outcomes in patients with cardiac amyloidosis. [23] [24] [25] [26] [27] [28] However, whether GLS is a useful marker for prognostication of survival in patients undergoing HCT independent of troponin and brain natriuretic peptide (BNP) remains unknown.
The objectives of this study were to investigate the prognostic implication of baseline (pretreatment) GLS and the added value of GLS beyond circulating cardiac biomarkers for risk stratification in patients with AL amyloidosis undergoing HCT.
METHODS

Study Population
Eighty-two patients with newly diagnosed biopsy-proven AL amyloidosis who received upfront treatment with HCT at Memorial Sloan Kettering Cancer Center between January 2007 and April 2014 were included in this study. Patients with more than two major organs involved, New York Heart Association class III or IV heart failure, or critical cardiac arrhythmias resulting in unstable hemodynamics were not eligible for HCT. Patients who received chemotherapy before HCT were excluded to eliminate any effect of prior potentially cardiotoxic exposure on baseline echocardiography and post-HCT outcomes. Hence, all baseline echocardiograms were obtained before any treatment. Clinical, laboratory, echocardiographic, and treatment data were extracted from a prospectively maintained database of an ongoing institutional review board protocol that prospectively collects baseline characteristics and outcomes of patients with systemic AL amyloidosis. One of the objectives of the protocol is to assess the prognostic value of cardiac characteristics such as laboratory and echocardiographic data in patients with AL amyloidosis receiving various types of treatment. Although the testing was performed as part of routine care, the data were prospectively collected with the intent of addressing the questions examined in the present study.
Patients were assigned a cardiac stage (mayo I, II, or III) on the basis of the cardiac biomarkers BNP and troponin. 9, 29 Conversion between BNP and NT-proBNP was as follows: log BNP = 0.28 + 0.66 Â log NT-proBNP; 86 pg/mO was identified as the appropriate cutoff. Stage I included patients with BNP < 86 ng/mL and troponin I (TnI) < 0.10 ng/mL, stage II included patients with either BNP $ 86 ng/mL or TnI $ 0.10 ng/mL, and stage III included patients with both BNP $ 86 ng/mL and TnI $ 0.10 ng/mL. 30 Left ventricular ejection fraction (LVEF) was calculated using the modified Simpson method. Mitral inflow velocity pattern was recorded from the apical four-chamber view with the pulsedwave Doppler sample volume positioned at the tips of the leaflets during diastole. Peak early filling (E-wave) and late diastolic filling (A-wave) velocities were measured and their ratio (mitral E/A) derived. Doppler tissue imaging of the mitral annulus was performed with measurement of the early (e 0 ) diastolic velocity at the lateral annulus. The studies were performed following a strain protocol. Images from the apical fourchamber, two-chamber, and three-chamber views were acquired sequentially to minimize heart rate variability. Three complete cardiac cycles per loop was recorded for each view to ensure that at least one complete cycle without any truncation was available for analysis. All images were acquired during a breath hold to avoid any breathing artifacts and minimize image translation. A high-quality electrocardiographic trace was obtained to allow proper gating of the images. Settings were optimized with utmost attention paid to the image quality and resolution of the endocardial border. The depth and the sector angle were adjusted to include the left ventricle but minimizing the sector size to achieve a higher frame rate, which was maintained between 40 and 90 frames/sec. All echocardiographic images were digitally archived in Digital Imaging and Communications in Medicine format on the echocardiography information management system and retrieved offline for GLS analysis.
Echocardiography
Myocardial Strain Measurement
GLS measurements were performed using vendor-independent offline 2D Cardiac Performance Analysis version 1.1.3 (TomTec Imaging Systems, Munich, Germany). The endocardial border was traced in end-diastole in the three apical views, which allowed the software to track myocardial movement throughout the cardiac cycle. After careful inspection, manual correction was performed if myocardial tracking was suboptimal. Each view was divided into six segments, for a total of 18 segments representing the entire left ventricle. Longitudinal strain curves were generated for each segment. GLS was calculated as the average value of the peak negative systolic strain values for all the segments within the three standard apical views. The negative nature of systolic strain or contraction can lead to confusion when describing increases or decreases in strain, as lower arithmetic value implies more vigorous contraction. For example, GLS of À20% implies better left ventricular (LV) systolic contraction but is lower in value than GLS of À14%. To avoid confusion, the normally negative GLS numbers are manually converted to positive numbers, as recommended in the 2015 American Society of Echocardiography guideline on cardiac chamber quantification, 31 such that the arithmetic value and the amplitude of contraction are concordant, allowing clearer communication of strain changes as an increase or decrease in the absolute value. GLS was measured by two well-trained operators (S.C.P., J.J.). All echocardiographic measurements were made with the operator blinded to the clinical and outcome data.
Reproducibility
Interobserver and intraobserver variability was assessed using the intraclass correlation coefficient. Bland-Altman plots were constructed by plotting the average of the two readings on the x axis versus the difference between the two readings on the y axis. The mean and SD of the differences were calculated. Because of the small sample size, the t distribution was used as the reference distribution to calculate the 95% limits of agreement. A P value < .05 was considered to indicate statistical significance. All statistical analyses were performed using either SAS version 9.2 (SAS Institute, Cary, NC) or R version 2.13.1 (R Core Development Team, Vienna, Austria). Interobserver variability was calculated by comparing the original GLS calculation with that calculated by a blinded second observer in 20 randomly selected patients. Intraobserver variability was calculated by repeated measurements in 20 patients by the primary reviewer 3 weeks after the initial measurement.
Statistical Analysis
Prospective follow-up began on the date of HCT. OS was the primary outcome. No patient was lost to follow-up during the study. Comparisons between groups were made using the Fisher exact test for categorical variables and the Wilcoxon rank sum test for continuous variables. The Spearman rank correlation coefficient was used to estimate the correlation between continuous variables. Differences between echocardiographic parameters and biomarkers before and after transplantation were evaluated using the Wilcoxon signed rank test. OS and survival stratified by categorical variables was estimated using the Kaplan-Meier method. The associations of baseline characteristics on OS were examined using the log-rank test for categorical variables and Cox proportional-hazards regression for continuous variables. There were too few events for a multivariate survival analysis. The cut point for GLS to predict OS was chosen using the maximally selected log-rank statistic (i.e., the cut point chosen best separates outcomes according to the maximum test statistic).
RESULTS
Baseline Patient Characteristics
Demographics and clinical features of 82 patients are summarized in Table 1 . Sixty-four percent of the patients had elevated troponin and/ or BNP, with 15% classified as Mayo stage III (elevated troponin and BNP). Baseline standard 2D echocardiographic parameters as well as GLS are shown in Table 2 . The mean LVEF was 65%, with only three patients having LVEFs < 50%. Although the mean GLS was 17%, which is the lower limit of normal, 20% of patients (16 of 82) had GLS < 12%, consistent with significant LV dysfunction, which has been associated with an adverse prognosis in other clinical settings. 32 The Spearman correlation coefficient of GLS with BNP was r = À0.46 (P < .0001) and with LVEF was r = 0.50 (P < .0001). GLS was not significantly correlated with TnI (r = -0.17, P = .15).
Pretreatment Predictors of Survival
Among 82 patients, 21 (25%) died. The median follow-up time for survivors was 58 months. GLS as well as cardiac biomarkers and mitral E/A ratio were identified as the strongest predictors of survival in the univariate analysis (P < .0001; Table 3 ). Other variables, including patient sex, difference in the involved and uninvolved free AL, and echocardiographic parameters of LV morphology and function, were also significantly associated with survival. Mayo cardiac stage was significantly associated with survival, with 5-year estimates of 93%, 72%, and 31% in cardiac stage I, II, and III patients, respectively (Figure 1) . GLS of 17% was identified as the value that best discriminated survivors from nonsurvivors. For the entire study population, patients with baseline GLS > 17% had 5-year survival of 95% compared with 47% in patients with GLS # 17% (Figure 2) . Among the 12 patients with Mayo stage III disease, nine patients (75%) had GLS # 17%, and three patients had GLS > 17%. By 5-year follow-up, only those three patients with GLS > 17% were alive, suggesting additional value of GLS for prognostication in this high-risk subgroup. Similarly for patients in Mayo stages I and II, GLS # 17% was associated with worse prognosis than GLS > 17% (Table 4 ). Multivariate analysis was not possible given the limited number of deaths.
Indices of Cardiac Structure and Function Following HCT
At 1 year following HCT, 48 patients (59%) were in CR. Fifty patients among the total population (61%) had 1-year post-HCT echocardiograms available. Among the patients in Mayo stages II and III, there was no significant change in GLS, interventricular septal thickness, mitral E/A ratio, or lateral E/e 0 ratio in the CR or non-CR group (Table 5) . LVEF decreased slightly in both groups. BNP or troponin also showed no change in the CR and the non-CR groups. *P value of comparison between GLS # 17% and GLS > 17%.
Journal of the American Society of Echocardiography
Volume 31 Number 1
Intraobserver and Interobserver Variability
For GLS, the intraclass correlation coefficient for interobserver agreement was 0.883 (95% CI, 0.732-0.952), and the intraclass correlation coefficient for intraobserver agreement was 0.923 (95% CI, 0.820-0.969), reflecting substantial agreement for measurement of GLS.
DISCUSSION
This is the first study to demonstrate the prognostic value of GLS for risk stratification among patients with AL amyloidosis undergoing HCT. Not only is GLS strongly prognostic, these data indicate that GLS provides additional information beyond the well-validated cardiac biomarker staging for survival among patients treated with HCT. High-dose chemotherapy coupled with HCT is one of the most effective treatments in AL amyloidosis. Elimination of pathologic plasma cells and suppression of amyloidogenic immunoglobulin AL production prevents further amyloid deposition and organ damage. Many centers have excluded patients with advanced cardiac involvement as determined by cardiac biomarker levels (Mayo stage III disease) from HCT as well as from clinical trials given, their overall poor prognosis. Our data suggests that functional assessment with GLS improves risk stratification of patients within each biomarker stage. Although GLS directly correlates with Mayo stage, 25% of the patients in Mayo stage III had GLS > 17%, and all were alive after 5 years of follow-up. Although this observation is based on a small number of patients, it suggests that the cardiac phenotype and prognosis are not uniform among patients classified within the same cardiac biomarker-based stage. The additional risk stratification provided by GLS may be useful in selecting appropriate patients for HCT and other investigational therapies.
This study confirms existing published data demonstrating the superiority of GLS as a predictor of survival compared with LVEF in patients with cardiac amyloidosis. 20, [22] [23] [24] It is well recognized that GLS, a measure of longitudinal LV function, is more sensitive and accurate than LVEF in the assessment of myocardial contractility, particularly in cardiomyopathic conditions. 33, 34 LVEF is often normal despite the presence of myocardial dysfunction in the presence of the low end-diastolic volume and small cavity size seen in patients with amyloid cardiomyopathy. Longitudinal LV mechanics, which are governed primarily by the subendocardial layer, are the most sensitive and vulnerable to myocardial disease. This likely explains why GLS remains a strong prognostic predictor despite normal LVEF in the present study population. Other investigators have also shown the incremental value of GLS for the assessment of outcome compared with clinical, echocardiographic, and serum biomarkers in patients with AL amyloidosis. 23, 27, 35 The variability in GLS cutoff values for the discrimination of survivors from nonsurvivors that has been reported in the literature is likely attributable to differences in the study population, duration of follow-up, treatment regimens, and platforms used for GLS analysis. Late gadolinium enhancement on cardiac magnetic resonance imaging has also been shown to provide incremental prognostic value over serum biomarkers in patients with cardiac amyloidosis. 22, [35] [36] [37] Ternacle et al 22 demonstrated a strong negative association between segmental LV longitudinal strain and amyloid burden measured by histopathology and late gadolinium enhancement. The study showed higher amyloid load with lower longitudinal strain from LV base to apex, providing further insight into the pathophysiology of the amyloid deposition and its contribution to myocardial contractile dysfunction.
The lack of improvement in cardiac structure and function among patients with and without CR 1 year after HCT is disappointing. However, it is possible that the small sample size limited the detection of such differences. Similarly, a recently published report by Salinaro et al 27 also failed to show improvement in wall thickness, GLS, LVEF, or diastolic function among patients who achieved CR. They did demonstrate mild improvement in the basal strain segments among patients in the CR group only. Although normalization of the precursor protein is a major predictor of survival in patients with AL amyloidosis, with studies demonstrating organ response in association with hematologic response, it may be of limited benefit to patients with persistent or progression of cardiac dysfunction, as suggested by these findings. It is possible that longer follow-up beyond 1 year is needed to detect any improvement of echocardiographic parameters after HCT. Larger studies with longer follow-up are needed to better define the long-term effect of hematologic remission on cardiac function. In addition, there are ongoing studies to explore the effect of novel therapy that directly targets amyloid deposits on organ function response. 38 
Study Limitations
This study was limited by its small population size and single-center design. Two-dimensional GLS is not standardized, and the cutoff identified in the present study may not be applicable when using a system other than the one used in the present study (2D Cardiac Performance Analysis) or studying patients with AL amyloidosis in different clinical settings. GLS of 17%, the lower limit of normal, identified as the cutoff to discriminate survivors from nonsurvivors, reflects the heterogeneity of the patient population with regard to the extent of cardiac involvement. But it was nevertheless predictive among patients within Mayo stages II and III. Given the small sample size, subgroup analysis for each Mayo stage to determine the optimal GLS cutoff was not possible. Larger studies are required to validate the optimal GLS cutoff for risk stratification. Classification of the Mayo staging system may not be exactly identical to the standard definition, as BNP was used instead of NT-proBNP, though both forms of the biomarker have been prognostically validated. We used the original staging system with cardiac biomarkers only and not the revised system, 39 which also includes an AL-based parameter, because the goal of our study was to investigate the added value of GLS to serum biomarkers for risk stratification.
CONCLUSIONS
GLS is a strong predictor of survival in patients with AL amyloidosis undergoing HCT, potentially roviding incremental value over serum cardiac biomarkers for risk stratification. GLS should be considered as a standard parameter along with serum cardiac biomarkers when evaluating eligibility for HCT or other investigational therapies.
